[go: up one dir, main page]

WO2011050008A9 - Combination therapy comprising administration of an amylinomimetic and a pyy peptidomimetic for effecting weight loss and for treating obesity and related metabolic conditions and disorders - Google Patents

Combination therapy comprising administration of an amylinomimetic and a pyy peptidomimetic for effecting weight loss and for treating obesity and related metabolic conditions and disorders Download PDF

Info

Publication number
WO2011050008A9
WO2011050008A9 PCT/US2010/053278 US2010053278W WO2011050008A9 WO 2011050008 A9 WO2011050008 A9 WO 2011050008A9 US 2010053278 W US2010053278 W US 2010053278W WO 2011050008 A9 WO2011050008 A9 WO 2011050008A9
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
amylinomimetic
pyy
peptidomimetic
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/053278
Other languages
French (fr)
Other versions
WO2011050008A2 (en
Inventor
Jonathan Todd Coffey
David G. Parkes
Jonathan David Roth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Publication of WO2011050008A2 publication Critical patent/WO2011050008A2/en
Anticipated expiration legal-status Critical
Publication of WO2011050008A9 publication Critical patent/WO2011050008A9/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods for treating obesity and obesity related disorders are disclosed. These methods include the use of at least: a first anti-obesity agent, or a derivative thereof; and a second anti-obesity agent or a derivative thereof.
PCT/US2010/053278 2009-10-19 2010-10-19 Combination therapy comprising administration of an amylinomimetic and a pyy peptidomimetic for effecting weight loss and for treating obesity and related metabolic conditions and disorders Ceased WO2011050008A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25306509P 2009-10-19 2009-10-19
US61/253,065 2009-10-19

Publications (2)

Publication Number Publication Date
WO2011050008A2 WO2011050008A2 (en) 2011-04-28
WO2011050008A9 true WO2011050008A9 (en) 2013-07-11

Family

ID=43900925

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/053278 Ceased WO2011050008A2 (en) 2009-10-19 2010-10-19 Combination therapy comprising administration of an amylinomimetic and a pyy peptidomimetic for effecting weight loss and for treating obesity and related metabolic conditions and disorders

Country Status (1)

Country Link
WO (1) WO2011050008A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US20160108098A1 (en) * 2013-05-02 2016-04-21 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
MA46990B1 (en) 2017-08-24 2024-03-29 Novo Nordisk As GLP-1 COMPOSITIONS AND ITS USES
JP2021522231A (en) * 2018-04-25 2021-08-30 ヤンセン ファーマシューティカ エヌ．ベー． Thioether Cyclic Peptide Amyrin Receptor Regulator
WO2020023621A1 (en) * 2018-07-24 2020-01-30 Puneeth Iyengar Improved weight loss therapy
TW202535454A (en) 2020-02-18 2025-09-16 丹麥商諾佛 儂迪克股份有限公司 Pharmaceutical formulations

Also Published As

Publication number Publication date
WO2011050008A2 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
WO2011050008A9 (en) Combination therapy comprising administration of an amylinomimetic and a pyy peptidomimetic for effecting weight loss and for treating obesity and related metabolic conditions and disorders
PH12017500930A1 (en) Hsp90 inhibitor combinations
WO2007144152A3 (en) Extended step-down estrogen regimen
WO2012068516A3 (en) Low dose cannabinoid medicaments
EP4079373A4 (en) Therapeutic ultrasound generation device, and handpiece for ultrasound treatment including same
WO2012103059A3 (en) Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
EP3632444A3 (en) Topical lfa-1 antagonists for use in localized treatment of immune related disorders
NZ601167A (en) Treatment of cardiac conditions
WO2012027065A3 (en) Combination therapy for treatment of disease
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
IL201479A (en) Use of tapentadol for the manufacture of a medicament for the treatment of pain
WO2009031606A1 (en) Therapeutic and prophylactic agents for arthritis
WO2010151565A3 (en) Combination therapies for the treatment of obesity
WO2011041632A3 (en) Combination therapies for the treatment of obesity
WO2010045417A3 (en) Combination therapies for the treatment of obesity
WO2010151503A3 (en) Combination therapies for the treatment of obesity
MX2012007898A (en) Methods of providing weight loss therapy in patients with major depression.
UA100527C2 (en) Benzothiazoles as ghrelin receptor modulators
MX2009010851A (en) Use of a composition comprising formoterol and beclometasone dipropionate for the prevention and/or treatment of an exacerbation of asthma.
WO2009144551A3 (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood
WO2010045522A3 (en) Combination therapies for the treatment of obesity
WO2011009115A3 (en) Combination therapies for the treatment of obesity
EP3735286A4 (en) Therapeutic agent delivery devices having integrated pain mitigation, and methods for using the same
WO2008097536A3 (en) Compositions and methods for treating psychiatric diseases and disorders
WO2011056850A3 (en) Linaclotide for the treatment of chronic constipation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10825562

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 10825562

Country of ref document: EP

Kind code of ref document: A2